Who was studied?
36 selected patients aged 75–93 years treated at one center.
What does the publication report?
Median PFS was 7.0 months and median OS 11.1 months. The abstract reports ORR 23.5% and DCR 70.6%; response denominators need full-text context.
Safety findings
34 patients had treatment-related events; three had grade 3 or higher events. No grade 5 events were observed.
How should we interpret it?
Small retrospective cohort with selection bias. It is distinct from the prospective PRaG 9.0 protocol.
Read the original source
This independently written summary was checked against the publicly available abstract. It is not a translation of the full paper or a clinical recommendation.
Safety and efficacy of PRaG therapy in elderly cancer patients · DOI: 10.1093/immadv/ltag019 · PMID: 42694766
Educational reporting, not individualized medical advice. Discuss treatment decisions with your clinical team.